2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders

Area of Science:

• Oncology
• Hematology
• Dermatology

Background:

• Cutaneous T-cell lymphoproliferative disorders (CTLDs) encompass conditions like mycosis fungoides and Sezary syndrome.
• Relapsed or refractory cases present significant treatment challenges.

Purpose of the Study:

• To assess the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) as a single agent in patients with relapsed or refractory CTLDs.
• To determine response rates and identify key adverse events associated with 2-CdA treatment.

Main Methods:

• A cohort of 25 patients with relapsed/refractory CTLDs received 2-CdA.
• Treatment involved varying durations of intravenous infusion (5-7 days) or bolus injection at 0.1 mg/kg/d.
• Cycles were administered every 28 days, with some patients receiving multiple cycles.

Main Results:

• An overall response rate of 24% was observed, including 12% complete responses and 12% partial responses.
• Median duration for complete response was 4.5 months and for partial response was 2 months.
• The most frequent toxicities were myelosuppression (64%) and infectious complications (64%).

Conclusions:

• 2-chlorodeoxyadenosine (2-CdA) demonstrates activity in previously treated, relapsed T-cell lymphoproliferative disorders.
• Significant myelosuppression and infectious complications necessitate careful monitoring and dose adjustments.